You might also like
Henry Schein, Inc. is a global company that operates in the health care distribution and technology sectors, providing a wide range of products and services to dental and medical professionals . The company distributes consumable products, dental specialty items, medical equipment, pharmaceuticals, and personal protective equipment, among other health care products . Additionally, Henry Schein offers technology and value-added services, including practice management software and consultancy services, to enhance the efficiency and effectiveness of health care practices .
-
Health Care Distribution - Distributes a comprehensive range of products including consumables, dental specialty products, medical equipment, pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, PPE, vitamins, and orthopedic implants .
- Dental Specialty Products - Offers implants, orthodontics, and endodontics products to dental practitioners and institutions .
- Medical Equipment and Supplies - Provides small and large equipment, equipment repair services, and branded and generic pharmaceuticals to medical facilities .
-
Technology and Value-Added Services - Provides software and technology solutions, including practice management systems, consultancy, education, revenue cycle management, financial services, e-services, and continuing education services to health care practitioners .
-
Corporate Brand Portfolio - Markets and sells a range of cost-effective, high-quality consumable merchandise products, including in vitro diagnostic devices, and manufactures certain dental specialty products .
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
James P. Breslawski ExecutiveBoard | Vice Chairman and President | Board Member, Henry Schein Cares Foundation; Leadership roles in dental industry organizations | Joined HSIC in 1980; held various leadership roles, including President since 2005 and Vice Chairman since 2018. Extensive experience in dental and healthcare markets. | |
Stanley M. Bergman ExecutiveBoard | Chairman and CEO | N/A | Joined HSIC in 1980; became Chairman and CEO in 1989. Led HSIC to become the world’s largest provider of healthcare solutions for office-based practitioners. | View Report → |
Lorelei McGlynn Executive | SVP and CHRO | Chairperson, 401(k) Plan Administrative Committee | Joined HSIC in 1999; became CHRO in 2013. Leads global HR strategy, focusing on culture, talent acquisition, diversity, and wellness initiatives. | |
Michael S. Ettinger Executive | EVP and COO | Board Member, Henry Schein Cares Foundation | Joined HSIC in 1994; became COO in 2022. Previously SVP of Corporate & Legal Affairs and Chief of Staff. Oversees global operations and corporate functions. | |
Ronald N. South Executive | SVP and CFO | Board Member, Henry Schein Cares Foundation | Joined HSIC in 2008; became CFO in 2022. Previously VP of Corporate Finance and Chief Accounting Officer. Extensive financial leadership experience. | |
Walter Siegel Executive | SVP and Chief Legal Officer | N/A | Joined HSIC in 2013; became Chief Legal Officer in 2021. Oversees legal, compliance, and regulatory functions. Previously General Counsel at Standard Microsystems Corporation. | |
Anne H. Margulies Board | Director | Board Member, HarborOne Bancorp; Board Member, SomaLogic; Advisory Board Member, Advanced Cyber Security Center | Joined HSIC’s board in 2018. Former CIO of Harvard University. Expertise in IT strategy, cybersecurity, and governance. | |
Bradley T. Sheares Board | Director | Board Member, Honeywell International; Board Member, Progressive Corporation | Joined HSIC’s board in 2010. Former CEO of Reliant Pharmaceuticals and President of U.S. Human Health at Merck. Extensive healthcare and pharmaceutical experience. | |
Carol Raphael Board | Director | National Advisor, Manatt Health Solutions; Chair, Long Term Quality Alliance; Board Member, Kaiser Permanente School of Medicine | Joined HSIC’s board in 2012. Former CEO of Visiting Nurse Service of New York. Expertise in healthcare policy, aging populations, and integrated care models. | |
Carole T. Faig Board | Director | Board Member, Cue Health; Board Member, Affinia Therapeutics; Board Member, QuVa Pharma; PATH | Joined HSIC’s board in 2023. Retired EY partner with 38 years of experience in healthcare and life sciences. Recognized for leadership in diversity and inclusion. | |
Deborah Derby Board | Director | CEO and Board Member, Carrols Restaurant Group | Joined HSIC’s board in 2021. Former President of Horizon Group USA and Vice Chairman of Toys “R” Us. Extensive experience in HR, strategy, and operations. | |
Joseph L. Herring Board | Director | N/A | Joined HSIC’s board in 2016. Former CEO of Covance Inc. and held leadership roles at Caremark International. Extensive experience in healthcare and clinical research organizations. | |
Kurt P. Kuehn Board | Director | Director, LocatorX; Member, SASB Standards Board | Joined HSIC’s board in 2016. Former CFO of UPS. Expertise in corporate finance, sustainability, and governance. | |
Max Lin Board | Director (Investor Designee) | President, KKR Hawaii Aggregator GP LLC | Joined HSIC’s board in 2025 as part of a strategic partnership with KKR. Extensive experience in private equity and investment management. | |
Mohamad Ali Board | Director | SVP and COO, IBM Consulting; Board Member, iRobot Corporation; Board Member, Oxfam America | Joined HSIC’s board in 2021. Extensive experience in technology and strategic transformations. Currently COO of IBM Consulting and serves on multiple boards. | |
Philip A. Laskawy Board | Lead Director | Board Member, Loews Corporation | Joined HSIC’s board in 2002. Former Chairman and CEO of Ernst & Young. Extensive experience in corporate finance, governance, and accounting standards. | |
Reed V. Tuckson Board | Director | Board Member, Adverum Biotechnologies; Board Member, CTI BioPharma; Founder, Black Coalition Against COVID-19 | Joined HSIC’s board in 2021. Former EVP at UnitedHealth Group. Expertise in public health, healthcare policy, and diversity initiatives. | |
Robert J. Hombach Board | Director | Board Member, BioMarin Pharmaceuticals; Board Member, Embecta Corporation | Joined HSIC’s board in 2025. Former CFO of Baxalta and Baxter International. Expertise in finance and healthcare strategy. | |
Scott Serota Board | Director | Board Member, Blue Cross Blue Shield of Michigan; Board Chair, Brain Research Foundation | Joined HSIC’s board in 2021. Former CEO of Blue Cross Blue Shield Association. Expertise in healthcare insurance, public policy, and business strategy. | |
William K. Daniel Board | Director (Investor Designee) | Executive Advisor, KKR | Joined HSIC’s board in 2025 as part of a strategic partnership with KKR. Former EVP at Danaher. Expertise in industrial and healthcare sectors. |
- Given the restructuring savings target of $75 million to $100 million by the end of 2025, what specific risks could hinder achieving these savings, and how confident are you in realizing operating margin expansion next year?
- With a shift towards lower-priced alternative and owned-brand dental products impacting sales but maintaining profitability, how do you plan to drive top-line growth while preserving margins amid increased competition from second-tier manufacturers?
- After losing customers to drug wholesalers due to last year's cyber incident, what specific strategies are you employing to regain market share in the medical distribution business, and how will you differentiate your services to prevent further customer attrition?
- Despite increasing your non-GAAP EPS guidance for 2024, you have lowered your total sales growth guidance; what factors are causing this divergence, and how sustainable is your EPS growth given the reduced sales outlook?
- Considering your significant investments in the global e-commerce platform leading to higher depreciation expenses, how confident are you that these investments will generate the anticipated growth to offset increased costs, especially with the planned U.S. launch next year?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
This competitor operates in the U.S. dental market and competes primarily on the basis of price, breadth of product line, e-commerce capabilities, customer service, and value-added products and services. | |
Benco Dental Supply Company | This competitor is another primary player in the U.S. dental market, competing on similar factors such as price, product line breadth, and customer service. |
This competitor is a national distributor in the U.S. medical market, which accounts for the majority of global medical sales. | |
Medline Industries, Inc. | This competitor is another national distributor in the U.S. medical market, competing alongside other regional and local distributors as well as manufacturers selling directly to end-users. |
Carestream Health, Inc. | This competitor operates in the dental software market, providing solutions that compete with the company's offerings. |
Carestream Dental LLC | This competitor also operates in the dental software market, offering products that compete with the company's software solutions. |
Centaur Software Development Co Pty Ltd. (d.b.a. dental4windows, dental4web) | This competitor provides dental software solutions and competes with the company's offerings in the dental software market. |
Open Dental Software, Inc. | This competitor is another player in the dental software market, offering solutions that compete with the company's products. |
PlanetDDS LLC | This competitor operates in the dental software market, providing solutions that compete with the company's offerings. |
Good Methods Global Inc. (d.b.a. CareStack) | This competitor provides dental software solutions and competes with the company's offerings in the dental software market. |
Curve Dental, LLC | This competitor is another player in the dental software market, offering solutions that compete with the company's products. |
This competitor operates in other software end markets, including revenue cycle management, patient relationship management, and patient demand generation. | |
EDI-Health Group, Inc. (d.b.a. Dental X Change, Inc.) | This competitor provides solutions in software end markets such as revenue cycle management and patient relationship management. |
This competitor operates in software end markets, including patient relationship management and demand generation. | |
Solutionreach, Inc. | This competitor provides solutions in patient relationship management and other software end markets. |
NextGen division of Quality Systems, Inc. | This competitor operates in the medical practice management and electronic medical records market, which is fragmented and competitive. |
eClinicalWorks | This competitor provides solutions in the medical practice management and electronic medical records market. |
This competitor operates in the medical practice management and electronic medical records market, competing with the company's offerings. | |
Epic Systems Corporation | This competitor is another player in the medical practice management and electronic medical records market. |
GACD Group | This competitor operates internationally in the dental and medical product distribution market, competing on price and customer service. |
Proclinic SA | This competitor is another international player in the dental and medical product distribution market. |
Lifco AB | This competitor operates internationally, competing in the dental and medical product distribution market. |
Planmeca Oy | This competitor is a significant player in the international dental and medical product distribution market. |
Billericay Dental Supply Co. Ltd. | This competitor operates internationally in the dental and medical product distribution market. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Acentus | 2025 | Henry Schein completed the acquisition of Acentus, a national medical supplier specializing in Continuous Glucose Monitors (CGMs), in January 2025 after announcing the deal in November 2024; the acquisition also brought on board Acentus’s founders to enhance its healthcare product offerings. |
Dental Distribution Business and Dental Affiliate in Europe | 2024 | Henry Schein acquired both a dental distribution business and a controlling interest in a European dental affiliate, with transactions completed on September 28, 2024, supporting the company’s strategy to expand its geographic footprint and dental distribution capabilities. |
TriMed Inc. | 2024 | Henry Schein acquired a 60% voting equity interest in TriMed Inc. for a total of $316 million, a move aimed at expanding its presence in the orthopedic market and leveraging synergies with existing product lines. |
S.I.N. Implant System | 2023 | Henry Schein completed the acquisition of S.I.N. Implant System on July 5, 2023, for $326 million in cash, thereby strengthening its dental implant portfolio and expanding its international distribution in Brazil and beyond. |
Biotech Dental | 2023 | Henry Schein acquired a 57% voting equity interest in Biotech Dental on April 5, 2023, for a total consideration of $423 million, integrating innovative dental implants, clear aligners, and digital software solutions with its practice management systems. |
Midway Dental | 2022 | Henry Schein completed the acquisition of Midway Dental on August 26, 2022, to bolster its presence in the Midwest U.S. market by integrating a reputable dental distribution business, despite initial slight GAAP dilution due to integration costs. |
Condor Dental | 2022 | The acquisition of Condor Dental in 2022 expanded Henry Schein’s geographic footprint in Switzerland by enhancing its dental distribution services and general dentistry offerings, augmenting its market presence where it previously had limited direct operations. |
Recent press releases and 8-K filings for HSIC.
- On April 7, 2025, Henry Schein, Inc. executed a Letter Agreement on Voting Commitment with KKR Hawaii Aggregator L.P., which is detailed in the 8‑K filing.
- The agreement allows the investor parties to vote at shareholder meetings based on independent voting recommendations when these differ from the Board’s recommendation, except in matters of director elections, while keeping the underlying Strategic Partnership Agreement unchanged.
- President James P. Breslawski will transition from his role as President effective April 1, 2025, to assume a new position as Senior Advisor.
- Breslawski will continue to serve on the Executive Management Committee, marking a significant management change.
- Intraoral scanner pricing trends were discussed, with scanners formerly priced around $30,000 now available at sub-$20,000 levels, boosting adoption and multi-chair utilization in dental practices.
- The company highlighted its implant business growth, noting successful acquisitions such as S.I.N. in Brazil and Biotech in France, which broadened its product portfolio with both sub-premium and value implants as well as clear aligner offerings.
- Innovation was underscored through collaborations like the vVARDIS partnership, which pairs the Curodont gel with digital diagnostic tools for early decay detection, enhancing patient outcomes.
- A strategic shift was noted with the KKR investment and the addition of new board members, aiming to drive operational efficiency, market share gains, and gross margin expansion.